Storys aus Switzerland

Neovii Pharmaceuticals AG

2

Neovii Pharmaceuticals AG announces new CEO

Galderma

Galderma: Combined Use of Rosacea Therapies Ivermectin 1% Cream and Brimonidine 0.33% Gel Evaluated in MOSAIC Study

Lausanne, Switzerland (ots/PRNewswire) - Today, the results of a study evaluating the combined use of topical rosacea treatments ivermectin 1% cream and brimonidine 0.33% gel were published in the Journal of Drugs in Dermatology. (Logo: http://mma.prnewswire.com/media/554005/Galderma_Logo.jpg ) "This is the first ...

Evalueserve

Evalueserve expands its Board

Schaffhausen/Zurich, Switzerland (ots) - Professional services provider Evalueserve welcomes Dr. Christian Casal and Armin Meier to its Board of Directors to strengthen its leadership team. Dr. Christian Casal is a former Director of McKinsey & Co. Inc. and Armin Meier is the owner and Managing Director of Boyden global executive search AG. Both executives bring to the Board extensive senior management and corporate governance experience from private and public companies ...

Clarendelle

Montreux Jazz Festival, Where Legends Inspire Young Talents

Paris and Montreux, Switzerland (ots/PRNewswire) - Clarendelle, exclusive foreign wine partner of the Montreux Jazz Festival Clarendelle joins the Montreux Jazz Festival by supporting the Montreux Jazz Artists Foundation in its mission to accompany the young talents of tomorrow. (Logo: http://mma.prnewswire.com/media/524397/Clarendelle_Logo.jpg ) (Logo: http://mma.prnewswire.com/media/529962/Montreux_Jazz_Arti ...

Debiopharm International SA

Debiopharm International SA and Arbor Pharmaceuticals, LLC Announce U.S. FDA Approval for Triptodur(TM), Triptorelin 6-month Formulation, in the Treatment of Central Precocious Puberty (CPP)

Lausanne, Switzerland and Atlanta, GA (ots) - Triptodur (TM), (triptorelin) for extended release injectable suspension, has been shown to arrest or reverse the clinical signs of puberty with once every six-month intramuscular injection (IM) dosing for children with CPP Approval brings new CPP treatment formulation ...

Shire Pharmaceuticals Group Plc

Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing Authorization Application for Treatment of Von Willebrand Disease

Zug, Switzerland (ots/PRNewswire) - VEYVONDI is the first and only recombinant von Willebrand factor treatment for adults with von Willebrand disease, the most common inherited bleeding disorder[1],[2],[3] Shire plc (LSE: SHP, NASDAQ: SHPG), the leading biotechnology company focused on serving individuals with rare ...

Debiopharm International SA

Almac Discovery and Debiopharm International SA Announce a Licensing Agreement for the Development of a Novel Wee-1 Inhibitor

Craigavon, N.I., UK, Lausanne, Switzerland (ots) - Almac Discovery (www.almacgroup.com/discovery), a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, and Debiopharm International SA (Debiopharm - www.debiopharm.com), a Switzerland based specialty ...

Berlinger Special AG

2

A new generation of anti-doping security bottles

Napapijri

Napapijri FW17 merges innovation and animal welfare / The new collection featuring the innovative Superlight Skidoo, is 100% down and fur free

Sonova

1

1

Making a dream come true - despite hearing loss, a dancing star is born in China

Debiopharm International SA

GenePOC announces FDA clearance for revogene(TM) instrument and its GBS LB test

Québec, Canada and Lausanne, Switzerland (ots) - GenePOC announces it received 510(k) clearance from the US Food and Drug Administration to market its first molecular assay to detect Group B Streptococcus and for the revogene molecular diagnostics instrument. GenePOC, Inc. (GenePOC) a member of the Debiopharm Group is pleased to announce that it has received FDA ...

Debiopharm International SA

Debiopharm International SA Announces Results from Phase I Dose-Escalation Study of Debio 1347/CH5183284

Lausanne, Switzerland (ots) - Debio 1347/CH5183284 was evaluated in patients with FGFR genomically activated advanced solid tumors Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced the results from the phase I ...

Debiopharm International SA

Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen

Lausanne, Switzerland and Waltham, Mass. (ots) - Transaction adds innovative clinical-stage program to expanding Debiopharm portfolio and broadens its clinical development expertise Divestiture aligns with ImmunoGen's focus on strategic growth initiatives and generates near-term value Debiopharm International SA ...

Shire Pharmaceuticals Group Plc

Shire to Highlight New Research Into Chronic Hypoparathyroidism at the European Congress of Endocrinology

Zug, Switzerland (ots/PRNewswire) - New clinical and real-life data in chronic hypoparathyroidism, to advance understanding of this rare disease and improve patients' lives Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in rare diseases, announced today new research to be presented on rhPTH(1-84) and on the ...

Debiopharm International SA

BC Platforms Closes USD $10 million Series B Financing led by Debiopharm and Tesi to accelerate knowledge platform development

Basel, Switzerland, Lausanne, Switzerland and Helsinki, Finland (ots) - Leading Big Data company developing platform with clinical and genomic data from 5 million subjects, to transform drug development and bring clinical benefits to patients. BC Platforms, a world leader in genomic data management solutions, today ...

Shire Pharmaceuticals Group Plc

Shire Granted EU Conditional Marketing Authorisation for Natpar[®] (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism

Zug, Switzerland (ots/PRNewswire) - Natpar is the first and only licensed recombinant human parathyroid hormone therapy for chronic hypoparathyroidism Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the European Commission (EC) has granted Conditional Marketing Authorisation for Natpar (rhPTH[1-84]), the ...

Shire Pharmaceuticals Group Plc

Shire Launches #PIPostsThanks Social Campaign to Raise Awareness of Primary Immunodeficiency (PI)

Zug, Switzerland (ots/PRNewswire) - Shire launches campaign to raise global awareness during World PI Week Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in rare diseases, is launching #PIPostsThanks, a social campaign to spotlight the unsung heroes who make a difference in the lives of people living with primary immunodeficiency (PI). PI is a group of nearly ...

Shire Pharmaceuticals Group Plc

Shire plc: Data Show A Bleeding Episode Occurs Every Three to 15 Seconds in People Living With Hemophilia Worldwide

Zug, Switzerland (ots/PRNewswire) - On World Hemophilia Day 2017, Shire challenges the community to collectively improve global standards of care for rare bleeding disorders Shire plc (LSE: SHP, NASDAQ: SHPG), a leading biotechnology company focused on serving individuals with rare diseases, joins the global ...

Shire Pharmaceuticals Group Plc

INTUNIV® (Guanfacine Hydrochloride Prolonged Release), a Non-stimulant for the Treatment of ADHD, Receives Approval in Japan

Zug, Switzerland (ots/PRNewswire) - A New Non-stimulant Clinical Option for Children and Adolescents From 6 to 17 Years old With ADHD Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that its partner in Japan, Shionogi & Co., Ltd, has received the approval of the Japanese Ministry of Health, Labor and Welfare to ...

Shire Pharmaceuticals Group Plc

Shire Receives European Approval for Label Extension of CINRYZE®(C1 inhibitor [human]) to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Paediatric Patients with HAE

Zug, Switzerland (ots/PRNewswire) - CINRYZE is now the first and only Hereditary angioedema treatment approved for routine prevention in paediatrics Shire plc (LSE: SHP, NASDAQ: SHPG) announced that the European Commission (EC) has approved a label extension granting three new indications for CINRYZE® (C1 inhibitor ...

Royal DSM

DSM and Evonik Establish Joint Venture for Omega-3 Fatty Acids From Natural Marine Algae for Animal Nutrition

Kaiseraugst, Switzerland (ots/PRNewswire) - - Breakthrough for animal nutrition to reduce impact on ocean resources and making it more sustainable - Commercial-scale facility for algal oil for salmon aquaculture and pet food to be built in the United States - Further develop and produce a high value algal oil with a ...

Shire Pharmaceuticals Group Plc

CHMP Recommends EU Conditional Marketing Authorisation for Natpar® (Parathyroid Hormone) for Patients with Chronic Hypoparathyroidism

Zug, Switzerland (ots/PRNewswire) - This Press Release is intended for Global Use If approved, Natpar would be the first licensed recombinant parathyroid hormone in Europe for the management of chronic hypoparathyroidism, the only endocrine-deficiency disorder with no hormone treatment[1] Shire plc (LSE: SHP, ...

Debiopharm International SA

GenePOC announces product launch in Europe and Middle East

Québec, Canada/Lausanne, Switzerland (ots) - GenePOC announces the commercialization of its Clostridium difficile and Group B Strep molecular tests in Europe, along with onboarding additional partners to cover the EMEA market GenePOC, Inc. (GenePOC) a member of the Debiopharm Group is proud to announce that it has started the commercialization of its first two CE-IVD marked tests, GenePOC(TM) CDiff and GenePOC(TM) GBS ...

Shire Pharmaceuticals Group Plc

New Data From Shire Aim To Help Close the Diagnosis and Treatment Gap for People With Hemophilia

Zug, Switzerland (ots/PRNewswire) - Shire presentations at EAHAD 2017 underscore the company's leadership in improving global standards of care Shire plc (LSE: SHP, NASDAQ: SHPG), the leading biotechnology company focused on serving individuals with rare diseases, presented its new estimate of the Global Annual Bleed Rate (GABR), an effort to build on current global ...